Matinas Bio Pharma Holdings Inc - Understand $mtnb stock

$MTNB Market Cap: $17.66 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$22.91M

TTM

Current Assets

$15.29M

Q2 2024

Current Liabilities

$2.392M

Q2 2024

Current Ratio

639.01%

Q2 2024

Total Assets

$24.37M

Q2 2024

Total Liabilities

$5.262M

Q2 2024

Book Value

$19.10M

Q2 2024

Cash

$4.216M

Q2 2024

P/E

-0.7707

Sep 18, 2024 EST

Free Cash Flow

-$9.014M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$1.096M	$3.188M	$33.33K	$158.3K	$89.81K	$119.8K	$149.7K	$0.00	$194.5K	$0.00
YoY Change	-65.62%	9464.96%	-78.95%	76.29%	-25.0%	-20.0%		-100.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$1.096M	$3.188M	$33.33K	$158.3K	$89.81K	$119.8K	$149.7K	$0.00	$194.5K	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Selling, General & Admin	$10.37M	$11.10M	$10.18M	$10.01M	$7.776M	$7.979M	$7.642M	$4.309M	$4.814M	$5.289M
YoY Change	-6.55%	8.99%	1.79%	28.67%	-2.54%	4.41%	77.32%	-10.48%	-8.99%
% of Gross Profit
Research & Development	$14.49M	$16.68M	$14.58M		$11.23M	$6.787M	$9.011M	$3.948M	$5.292M	$5.176M	$1.761M
YoY Change	-13.13%	14.36%			65.52%	-24.67%	128.25%	-25.41%	2.25%	193.82%
% of Gross Profit
Depreciation & Amortization	$393.0K	$337.0K	$280.1K	$290.0K	$328.8K	$218.3K	$100.6K	$52.64K	$43.50K	$41.58K	$1.131K
YoY Change	16.62%	20.3%	-3.41%	-11.78%	50.59%	116.99%	91.11%	21.02%	4.62%	3576.48%
% of Gross Profit
Operating Expenses	$24.86M	$16.68M	$24.77M	$0.00	$19.01M	$14.77M	$16.65M	$8.257M	$10.11M	$10.46M	$3.712M
YoY Change	49.07%	-32.66%		-100.0%	28.74%	-11.32%	101.67%	-18.29%	-3.43%	181.89%
Operating Profit	-$23.77M	-$24.59M	-$24.74M					-$8.257M	-$9.911M	-$10.46M	-$3.712M
YoY Change	-3.35%	-0.59%						-16.69%	-5.29%	181.89%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Interest Expense				$686.4K	$541.3K	$56.55K	$22.03K	-$16.51K	$19.63K	-$25.17K
YoY Change				26.81%	857.21%	156.7%	-233.43%	-184.11%	-177.99%
% of Operating Profit
Other Income/Expense, Net	$340.0K	$102.0K	$122.9K					-$16.51K	$19.63K	-$25.17K	-$688.00
YoY Change	233.33%	-16.99%						-184.09%	-177.97%	3558.87%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Pretax Income	-$22.94M	-$21.00M	-$23.28M	-$22.45M	-$17.37M	-$14.59M	-$15.84M	-$7.599M	-$9.135M	-$10.22M
YoY Change	9.26%	-9.82%	3.73%	29.21%	19.07%	-7.91%	108.5%	-16.82%	-10.62%
Income Tax						-$506.9K	-$357.0K			$270.0K
% Of Pretax Income
Net Earnings	-$22.94M	-$21.00M	-$23.28M	-$22.45M	-$17.37M	-$14.08M	-$15.49M	-$7.599M	$7.100M	-$10.22M	-$3.713M
YoY Change	9.26%	-9.82%	3.73%	29.21%	23.36%	-9.06%	103.8%	-207.02%	-169.46%	175.27%
Net Earnings / Revenue	-2093.25%	-658.63%	-69857.25%	-14177.25%	-19343.78%	-11760.39%	-10345.71%		3650.5%
Basic Earnings Per Share	-$0.11	-$0.10	-$0.11
Diluted Earnings Per Share	-$0.11	-$0.10	-$110.8K	-$114.0K	-$119.7K	-$143.6K	-$171.2K	-$131.8K	-$177.5K	-$318.6K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$13.76M	$28.76M	$49.62M	$58.68M	$27.78M	$12.45M	$7.307M	$4.105M	$3.227M	$2.591M	$10.84M	$420.0K	$0.00
YoY Change	-52.17%	-42.04%	-15.44%	111.27%	123.15%	70.35%	77.97%	27.22%	24.56%	-76.1%	2480.95%
Cash & Equivalents	$4.787M	$6.830M	$21.03M	$12.43M	$22.17M	$12.45M	$7.307M	$4.105M	$3.227M	$2.591M	$10.84M	$420.0K	$0.00
Short-Term Investments	$8.969M	$21.93M	$28.59M	$46.25M	$5.605M
Other Short-Term Assets	$1.787M	$5.769M	$1.371M	$2.876M	$2.148M	$638.6K	$657.5K	$460.0K	$332.1K	$214.4K	$80.00K	$0.00
YoY Change	-69.02%	320.64%	-52.31%	33.9%	236.3%	-2.86%	42.91%	38.51%	54.89%	168.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$15.54M	$34.53M	$50.99M	$61.55M	$29.92M	$13.09M	$7.964M	$4.565M	$3.559M	$2.805M	$10.92M	$420.0K	$0.00
YoY Change	-54.99%	-32.28%	-17.16%	105.71%	128.67%	64.31%	74.44%	28.28%	26.88%	-74.31%	2500.0%
Property, Plant & Equipment	$5.008M	$5.734M	$5.779M	$4.859M	$5.627M	$2.043M	$1.570M	$356.1K	$377.7K	$340.0K	$90.00K	$0.00
YoY Change	-12.66%	-0.78%	18.94%	-13.66%	175.46%	30.13%	340.8%	-5.71%	11.09%	277.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$200.0K	$200.0K	$200.0K	$336.0K	$461.0K	$536.0K	$540.9K	$115.4K	$216.3K	$320.0K	$0.00
YoY Change	0.0%	0.0%	0.0%	-40.48%	-27.11%	-13.99%	-0.9%	368.8%	-46.67%	-32.4%
Total Long-Term Assets	$9.561M	$10.29M	$10.33M	$9.412M	$10.32M	$6.858M	$6.460M	$5.251M	$4.847M	$556.3K	$410.0K	$0.00	$0.00
YoY Change	-7.06%	-0.44%	9.78%	-8.77%	50.45%	6.16%	23.02%	8.33%	771.27%	35.69%
Total Assets	$25.10M	$44.82M	$61.33M	$70.97M	$40.24M	$19.94M	$14.42M	$9.816M	$8.406M	$3.361M	$11.33M	$420.0K	$0.00
YoY Change
Accounts Payable	$514.0K	$618.0K	$938.3K	$349.9K	$679.3K	$295.7K	$582.9K	$475.6K	$497.8K	$271.2K	$400.0K	$60.00K	$0.00
YoY Change	-16.83%	-34.13%	168.12%	-48.49%	129.77%	-49.28%	22.55%	-4.47%	83.6%	-32.21%	566.67%
Accrued Expenses	$2.103M	$2.940M	$2.457M	$2.544M	$2.263M	$1.087M	$959.2K	$829.7K	$610.2K	$802.8K	$460.0K	$0.00
YoY Change	-28.47%	19.64%	-3.4%	12.4%	108.24%	13.32%	15.6%	35.97%	-23.99%	74.51%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$199.8K	$170.2K	$118.1K	$0.00	$0.00	$0.00	$20.00K	$0.00
YoY Change					-100.0%	17.39%	44.21%				-100.0%
Long-Term Debt Due	$5.000K	$7.000K	$21.04K	$30.85K	$54.67K	$83.25K	$26.98K	$9.940K	$11.26K	$44.36K
YoY Change	-28.57%	-66.73%	-31.8%	-43.57%	-34.33%	208.56%	171.43%	-11.72%	-74.62%
Total Short-Term Liabilities	$2.622M	$4.286M	$4.349M	$3.568M	$3.097M	$2.840M	$1.769M	$1.445M	$1.129M	$1.118M	$860.0K	$80.00K	$0.00
YoY Change	-38.82%	-1.44%	21.89%	15.19%	9.06%	60.52%	22.45%	28.02%	0.92%	30.03%	975.0%
Long-Term Debt	$18.00K	$22.00K	$2.620K	$23.66K	$54.51K	$107.7K	$67.68K	$16.45K	$0.00	$15.29K	$0.00	$460.0K	$0.00
YoY Change	-18.18%	739.69%	-88.93%	-56.6%	-49.37%	59.07%	311.43%		-100.0%		-100.0%
Other Long-Term Liabilities	$2.877M	$3.533M	$4.140M	$3.304M	$3.696M	$512.7K	$1.057M			$0.00
YoY Change	-18.57%	-14.67%	25.31%	-10.59%	620.8%	-51.48%
Total Long-Term Liabilities	$2.895M	$3.555M	$4.143M	$3.328M	$3.750M	$620.4K	$1.124M	$16.45K	$0.00	$15.29K	$0.00	$460.0K	$0.00
YoY Change	-18.57%	-14.19%	24.5%	-11.26%	504.5%	-44.83%	6735.14%		-100.0%		-100.0%
Total Liabilities	$5.858M	$8.182M	$8.833M	$7.237M	$7.189M	$3.802M	$3.742M	$2.666M	$2.334M	$1.134M	$860.0K	$540.0K	$0.00
YoY Change	-28.4%	-7.37%	22.06%	0.67%	89.1%	1.6%	40.33%	14.26%	105.87%	31.81%	59.26%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	217.3M shares	216.8M shares	210.2M shares
Diluted Shares Outstanding	217.3M shares	216.8M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $17.657 Million

About Matinas BioPharma Holdings Inc

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 32 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. The company is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. The company is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.

Industry: Pharmaceutical Preparations Peers: Anixa Biosciences Inc Capricor Therapeutics Inc CEL-SCI Corp PARDES BIOSCIENCES, INC. IPI Legacy Liquidation Co Jounce Therapeutics, Inc. Larimar Therapeutics Inc Precision BioSciences Inc Werewolf Therapeutics Inc